Matthew McQueen
Concepts (435)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Genome-Wide Association Study | 22 | 2022 | 1334 | 2.020 |
Why?
| Polymorphism, Single Nucleotide | 39 | 2020 | 2070 | 1.800 |
Why?
| Genetic Predisposition to Disease | 26 | 2022 | 2270 | 1.460 |
Why?
| Genetic Linkage | 10 | 2011 | 298 | 1.360 |
Why?
| Waist-Height Ratio | 3 | 2016 | 7 | 1.070 |
Why?
| Risk-Taking | 4 | 2015 | 344 | 0.870 |
Why?
| Body Mass Index | 12 | 2015 | 2244 | 0.850 |
Why?
| Genetic Testing | 9 | 2016 | 424 | 0.750 |
Why?
| Sexual Behavior | 3 | 2013 | 453 | 0.710 |
Why?
| Bipolar Disorder | 5 | 2011 | 232 | 0.690 |
Why?
| Alcohol Drinking | 6 | 2022 | 742 | 0.680 |
Why?
| Siblings | 7 | 2014 | 220 | 0.660 |
Why?
| Quantitative Trait, Heritable | 5 | 2016 | 119 | 0.610 |
Why?
| Epidemiology | 1 | 2018 | 15 | 0.600 |
Why?
| Genome, Human | 9 | 2014 | 393 | 0.600 |
Why?
| Genotype | 18 | 2019 | 1834 | 0.590 |
Why?
| Substance-Related Disorders | 8 | 2020 | 1019 | 0.570 |
Why?
| Metabolic Syndrome | 2 | 2016 | 339 | 0.570 |
Why?
| Quantitative Trait Loci | 4 | 2015 | 355 | 0.560 |
Why?
| Alzheimer Disease | 8 | 2011 | 509 | 0.530 |
Why?
| Brain Concussion | 2 | 2021 | 543 | 0.530 |
Why?
| Cardiovascular Diseases | 10 | 2024 | 2013 | 0.520 |
Why?
| Databases, Genetic | 5 | 2012 | 226 | 0.520 |
Why?
| Longitudinal Studies | 15 | 2024 | 2668 | 0.510 |
Why?
| Teaching | 1 | 2018 | 209 | 0.510 |
Why?
| Education, Medical, Undergraduate | 1 | 2018 | 174 | 0.500 |
Why?
| Antisocial Personality Disorder | 2 | 2015 | 162 | 0.500 |
Why?
| Alcoholism | 8 | 2020 | 759 | 0.500 |
Why?
| Waist Circumference | 1 | 2015 | 137 | 0.490 |
Why?
| Athletic Injuries | 2 | 2021 | 517 | 0.480 |
Why?
| Receptors, Nicotinic | 7 | 2013 | 323 | 0.480 |
Why?
| Genetic Variation | 8 | 2022 | 935 | 0.470 |
Why?
| Obesity | 8 | 2016 | 2844 | 0.450 |
Why?
| Humans | 105 | 2024 | 128896 | 0.440 |
Why?
| Tobacco Use Disorder | 6 | 2020 | 241 | 0.440 |
Why?
| Impulsive Behavior | 1 | 2015 | 128 | 0.440 |
Why?
| Public Health | 1 | 2018 | 493 | 0.430 |
Why?
| Gene-Environment Interaction | 2 | 2014 | 185 | 0.420 |
Why?
| Blood Pressure | 8 | 2018 | 1743 | 0.410 |
Why?
| Aging | 6 | 2020 | 1767 | 0.410 |
Why?
| Predictive Value of Tests | 3 | 2018 | 1967 | 0.390 |
Why?
| Male | 66 | 2024 | 63146 | 0.390 |
Why?
| Conduct Disorder | 5 | 2015 | 198 | 0.390 |
Why?
| Breast Feeding | 1 | 2015 | 423 | 0.380 |
Why?
| Natriuretic Peptide, Brain | 4 | 2024 | 101 | 0.370 |
Why?
| Female | 62 | 2024 | 68162 | 0.370 |
Why?
| Phenotype | 17 | 2020 | 3059 | 0.360 |
Why?
| Genetic Loci | 4 | 2022 | 274 | 0.360 |
Why?
| Carrier State | 2 | 2021 | 60 | 0.350 |
Why?
| Troponin T | 3 | 2020 | 57 | 0.350 |
Why?
| Chromosomes, Human, Pair 6 | 2 | 2010 | 52 | 0.330 |
Why?
| Pedigree | 3 | 2013 | 491 | 0.320 |
Why?
| Troponin I | 2 | 2020 | 75 | 0.310 |
Why?
| Adult | 34 | 2020 | 35361 | 0.310 |
Why?
| Apolipoprotein E4 | 2 | 2007 | 34 | 0.300 |
Why?
| Apolipoprotein E2 | 1 | 2007 | 3 | 0.300 |
Why?
| alpha-Macroglobulins | 1 | 2007 | 25 | 0.290 |
Why?
| Biometry | 2 | 2007 | 67 | 0.290 |
Why?
| Young Adult | 17 | 2021 | 12286 | 0.290 |
Why?
| Adolescent | 24 | 2021 | 20197 | 0.280 |
Why?
| Body Weight | 5 | 2015 | 931 | 0.280 |
Why?
| Multifactorial Inheritance | 2 | 2022 | 148 | 0.270 |
Why?
| Sodium, Dietary | 3 | 2018 | 40 | 0.260 |
Why?
| Sodium | 2 | 2018 | 203 | 0.260 |
Why?
| Family | 7 | 2011 | 650 | 0.260 |
Why?
| Risk Factors | 21 | 2022 | 9792 | 0.260 |
Why?
| Acute Coronary Syndrome | 2 | 2020 | 267 | 0.260 |
Why?
| Myocardial Infarction | 5 | 2020 | 1031 | 0.260 |
Why?
| Memory | 1 | 2007 | 231 | 0.260 |
Why?
| Linkage Disequilibrium | 7 | 2020 | 255 | 0.250 |
Why?
| Middle Aged | 30 | 2024 | 30977 | 0.250 |
Why?
| Chromosomes, Human, Pair 8 | 1 | 2005 | 36 | 0.250 |
Why?
| Sodium Nitrite | 2 | 2015 | 39 | 0.250 |
Why?
| Models, Genetic | 8 | 2016 | 586 | 0.240 |
Why?
| Asymptomatic Infections | 2 | 2021 | 23 | 0.240 |
Why?
| Feeding and Eating Disorders | 2 | 2020 | 123 | 0.230 |
Why?
| Diet, Sodium-Restricted | 2 | 2016 | 36 | 0.230 |
Why?
| HIV Infections | 3 | 2013 | 2696 | 0.230 |
Why?
| Myocardium | 2 | 2020 | 981 | 0.230 |
Why?
| Internationality | 2 | 2022 | 148 | 0.220 |
Why?
| Endothelium, Vascular | 3 | 2016 | 917 | 0.220 |
Why?
| Aged | 25 | 2024 | 22035 | 0.210 |
Why?
| Health Status | 2 | 2018 | 750 | 0.210 |
Why?
| Population Health | 1 | 2024 | 46 | 0.210 |
Why?
| Cooperative Behavior | 1 | 2005 | 427 | 0.210 |
Why?
| Viral Load | 2 | 2021 | 448 | 0.200 |
Why?
| Saliva | 2 | 2021 | 204 | 0.200 |
Why?
| Lipids | 3 | 2018 | 614 | 0.200 |
Why?
| Cholesterol, HDL | 3 | 2016 | 203 | 0.200 |
Why?
| Tobacco Use | 1 | 2022 | 59 | 0.200 |
Why?
| Nerve Tissue Proteins | 4 | 2011 | 568 | 0.200 |
Why?
| Prospective Studies | 9 | 2021 | 7060 | 0.190 |
Why?
| Case-Control Studies | 14 | 2019 | 3334 | 0.190 |
Why?
| Peptide Fragments | 4 | 2024 | 694 | 0.190 |
Why?
| Clinical Laboratory Techniques | 2 | 2020 | 86 | 0.190 |
Why?
| Gastrointestinal Microbiome | 2 | 2020 | 635 | 0.180 |
Why?
| Neuropsychological Tests | 2 | 2021 | 994 | 0.180 |
Why?
| Receptors, GABA-A | 2 | 2014 | 93 | 0.180 |
Why?
| Mental Disorders | 3 | 2019 | 1024 | 0.180 |
Why?
| Serotonin Plasma Membrane Transport Proteins | 2 | 2012 | 74 | 0.180 |
Why?
| Prediabetic State | 1 | 2024 | 242 | 0.180 |
Why?
| Reproducibility of Results | 2 | 2021 | 3042 | 0.180 |
Why?
| Alleles | 5 | 2018 | 847 | 0.180 |
Why?
| Hypertension | 3 | 2016 | 1236 | 0.170 |
Why?
| Diseases in Twins | 2 | 2012 | 174 | 0.170 |
Why?
| Gene Frequency | 10 | 2011 | 503 | 0.170 |
Why?
| Smoking | 4 | 2019 | 1501 | 0.170 |
Why?
| Brachial Artery | 3 | 2016 | 205 | 0.170 |
Why?
| Data Interpretation, Statistical | 3 | 2011 | 336 | 0.160 |
Why?
| Surgical Procedures, Operative | 2 | 2014 | 249 | 0.160 |
Why?
| Multigene Family | 2 | 2011 | 197 | 0.160 |
Why?
| Genetic Markers | 4 | 2014 | 335 | 0.160 |
Why?
| Minisatellite Repeats | 1 | 2019 | 40 | 0.160 |
Why?
| Feces | 2 | 2020 | 430 | 0.150 |
Why?
| Behavior | 1 | 2019 | 92 | 0.150 |
Why?
| Adolescent Behavior | 2 | 2013 | 498 | 0.150 |
Why?
| Healthy Aging | 1 | 2018 | 32 | 0.150 |
Why?
| Global Health | 3 | 2016 | 317 | 0.150 |
Why?
| Biological Specimen Banks | 1 | 2019 | 101 | 0.150 |
Why?
| Schizophrenia | 3 | 2020 | 433 | 0.150 |
Why?
| Pandemics | 2 | 2024 | 1516 | 0.150 |
Why?
| Risk | 3 | 2020 | 866 | 0.150 |
Why?
| Genetic Association Studies | 4 | 2014 | 356 | 0.150 |
Why?
| Reference Values | 3 | 2016 | 791 | 0.150 |
Why?
| Students | 2 | 2021 | 576 | 0.150 |
Why?
| Sodium Pertechnetate Tc 99m | 2 | 1997 | 6 | 0.150 |
Why?
| Vascular Stiffness | 3 | 2018 | 479 | 0.140 |
Why?
| Body Height | 2 | 2015 | 191 | 0.140 |
Why?
| Likelihood Functions | 2 | 2015 | 135 | 0.140 |
Why?
| Marijuana Abuse | 1 | 2020 | 230 | 0.140 |
Why?
| Burns | 1 | 2021 | 286 | 0.140 |
Why?
| NAD | 1 | 2018 | 71 | 0.140 |
Why?
| Niacinamide | 1 | 2018 | 73 | 0.140 |
Why?
| Caloric Restriction | 2 | 2018 | 108 | 0.140 |
Why?
| Athletes | 1 | 2021 | 407 | 0.140 |
Why?
| Mouth | 1 | 2017 | 81 | 0.140 |
Why?
| Exercise | 2 | 2018 | 1923 | 0.140 |
Why?
| Apolipoprotein B-100 | 1 | 2016 | 10 | 0.140 |
Why?
| Hair | 2 | 2015 | 73 | 0.140 |
Why?
| Cholesterol, LDL | 2 | 2016 | 360 | 0.140 |
Why?
| Psychological Trauma | 1 | 2017 | 54 | 0.130 |
Why?
| Apolipoprotein A-I | 1 | 2016 | 29 | 0.130 |
Why?
| Regional Blood Flow | 2 | 2016 | 462 | 0.130 |
Why?
| Risk Assessment | 6 | 2016 | 3286 | 0.130 |
Why?
| Chromosome Mapping | 5 | 2015 | 503 | 0.130 |
Why?
| Trehalose | 1 | 2016 | 30 | 0.130 |
Why?
| Receptors, Metabotropic Glutamate | 1 | 2016 | 39 | 0.130 |
Why?
| Gene Regulatory Networks | 2 | 2018 | 278 | 0.130 |
Why?
| Cross-Sectional Studies | 5 | 2013 | 5032 | 0.120 |
Why?
| Sexual Partners | 2 | 2013 | 179 | 0.120 |
Why?
| United States | 5 | 2016 | 13975 | 0.120 |
Why?
| Amino Acids | 1 | 2018 | 469 | 0.120 |
Why?
| Educational Status | 2 | 2014 | 458 | 0.120 |
Why?
| Europe | 4 | 2022 | 366 | 0.120 |
Why?
| Adolescent Medicine | 1 | 2014 | 34 | 0.110 |
Why?
| ROC Curve | 1 | 2016 | 500 | 0.110 |
Why?
| Quality Control | 1 | 2014 | 154 | 0.110 |
Why?
| Proteome | 1 | 2018 | 423 | 0.110 |
Why?
| Carotid Arteries | 1 | 2015 | 207 | 0.110 |
Why?
| Health Surveys | 1 | 2016 | 485 | 0.110 |
Why?
| Malawi | 1 | 2013 | 47 | 0.110 |
Why?
| Hindlimb | 1 | 2014 | 126 | 0.110 |
Why?
| Telomere | 1 | 2016 | 231 | 0.110 |
Why?
| Metabolomics | 1 | 2018 | 592 | 0.110 |
Why?
| Income | 1 | 2014 | 191 | 0.110 |
Why?
| Albuminuria | 1 | 2014 | 180 | 0.110 |
Why?
| Locomotion | 1 | 2014 | 98 | 0.110 |
Why?
| Colorado | 4 | 2021 | 4443 | 0.100 |
Why?
| Nervous System Physiological Phenomena | 1 | 2013 | 21 | 0.100 |
Why?
| Aorta | 1 | 2015 | 410 | 0.100 |
Why?
| Transplantation | 1 | 2013 | 25 | 0.100 |
Why?
| Polymorphism, Genetic | 3 | 2012 | 641 | 0.100 |
Why?
| Patient Outcome Assessment | 1 | 2014 | 128 | 0.100 |
Why?
| Physical Exertion | 1 | 2014 | 215 | 0.100 |
Why?
| Metabolic Networks and Pathways | 1 | 2014 | 176 | 0.100 |
Why?
| DEAD-box RNA Helicases | 1 | 2013 | 61 | 0.100 |
Why?
| Myocardial Ischemia | 1 | 2014 | 254 | 0.100 |
Why?
| Pravastatin | 1 | 1992 | 27 | 0.100 |
Why?
| Substance Abuse, Intravenous | 1 | 2013 | 106 | 0.100 |
Why?
| Lovastatin | 1 | 1992 | 27 | 0.100 |
Why?
| Receptors, Oxytocin | 1 | 2012 | 23 | 0.100 |
Why?
| Genetic Heterogeneity | 3 | 2008 | 54 | 0.100 |
Why?
| Age Factors | 6 | 2020 | 3133 | 0.100 |
Why?
| Hyperlipoproteinemia Type II | 1 | 1992 | 34 | 0.100 |
Why?
| Puberty | 1 | 2013 | 143 | 0.090 |
Why?
| Haplotypes | 6 | 2010 | 473 | 0.090 |
Why?
| Software | 2 | 2014 | 611 | 0.090 |
Why?
| Biomarkers | 5 | 2024 | 3874 | 0.090 |
Why?
| Physical Fitness | 1 | 2013 | 200 | 0.090 |
Why?
| Chromosomes, Human, Pair 18 | 1 | 2011 | 9 | 0.090 |
Why?
| Chromosomes, Human, Pair 9 | 1 | 2011 | 39 | 0.090 |
Why?
| Chromosomes, Human, Pair 17 | 1 | 2011 | 55 | 0.090 |
Why?
| Postural Balance | 1 | 2014 | 208 | 0.090 |
Why?
| Receptors, Immunologic | 2 | 2013 | 213 | 0.090 |
Why?
| Aged, 80 and over | 5 | 2020 | 7050 | 0.090 |
Why?
| Interleukins | 1 | 2013 | 245 | 0.090 |
Why?
| Receptors, Dopamine D4 | 1 | 2011 | 26 | 0.090 |
Why?
| Double-Blind Method | 4 | 2018 | 1858 | 0.090 |
Why?
| Diabetes Mellitus, Type 2 | 2 | 2024 | 2421 | 0.090 |
Why?
| Motor Activity | 1 | 2015 | 666 | 0.090 |
Why?
| Dopamine Plasma Membrane Transport Proteins | 1 | 2011 | 47 | 0.090 |
Why?
| Glucose Metabolism Disorders | 1 | 2010 | 11 | 0.090 |
Why?
| Behavior, Animal | 1 | 2014 | 482 | 0.090 |
Why?
| Odds Ratio | 4 | 2016 | 1019 | 0.090 |
Why?
| Child Behavior Disorders | 1 | 2011 | 133 | 0.090 |
Why?
| Catechol O-Methyltransferase | 1 | 2010 | 18 | 0.090 |
Why?
| Hepatitis C | 1 | 2013 | 234 | 0.080 |
Why?
| Tissue Donors | 1 | 2013 | 398 | 0.080 |
Why?
| Quality of Life | 1 | 2021 | 2706 | 0.080 |
Why?
| Life Expectancy | 1 | 2010 | 55 | 0.080 |
Why?
| Diet, Reducing | 1 | 2010 | 82 | 0.080 |
Why?
| Microbiota | 1 | 2017 | 724 | 0.080 |
Why?
| Psychology, Adolescent | 1 | 2009 | 63 | 0.080 |
Why?
| Environment | 2 | 2010 | 346 | 0.080 |
Why?
| Stress Disorders, Post-Traumatic | 1 | 2017 | 828 | 0.080 |
Why?
| Twins, Dizygotic | 1 | 2010 | 180 | 0.080 |
Why?
| Energy Metabolism | 1 | 2015 | 837 | 0.080 |
Why?
| Hyperhomocysteinemia | 1 | 2009 | 26 | 0.080 |
Why?
| Twins, Monozygotic | 1 | 2010 | 207 | 0.080 |
Why?
| Longevity | 1 | 2010 | 150 | 0.080 |
Why?
| Genes, Neoplasm | 1 | 2008 | 20 | 0.080 |
Why?
| Surveys and Questionnaires | 3 | 2024 | 5355 | 0.080 |
Why?
| Homocysteine | 1 | 2009 | 150 | 0.080 |
Why?
| Prevalence | 5 | 2013 | 2540 | 0.080 |
Why?
| Raphe Nuclei | 2 | 1999 | 111 | 0.070 |
Why?
| Myosin Type V | 1 | 2008 | 9 | 0.070 |
Why?
| Canada | 3 | 2007 | 355 | 0.070 |
Why?
| Cognition | 1 | 2015 | 1093 | 0.070 |
Why?
| Universities | 2 | 2021 | 404 | 0.070 |
Why?
| Vitamins | 1 | 2009 | 171 | 0.070 |
Why?
| Severity of Illness Index | 2 | 2013 | 2767 | 0.070 |
Why?
| Myosin Heavy Chains | 1 | 2008 | 173 | 0.070 |
Why?
| Attention Deficit Disorder with Hyperactivity | 1 | 2011 | 379 | 0.070 |
Why?
| Parkinson Disease | 1 | 2012 | 408 | 0.070 |
Why?
| Task Performance and Analysis | 1 | 2007 | 174 | 0.070 |
Why?
| Atrial Natriuretic Factor | 1 | 2006 | 56 | 0.070 |
Why?
| Triglycerides | 2 | 2003 | 519 | 0.070 |
Why?
| Pharmacogenetics | 1 | 2007 | 170 | 0.060 |
Why?
| Chromosomes, Human, Pair 4 | 1 | 2005 | 29 | 0.060 |
Why?
| Sensitivity and Specificity | 2 | 2021 | 1840 | 0.060 |
Why?
| Membrane Glycoproteins | 1 | 2008 | 465 | 0.060 |
Why?
| Antigens, Neoplasm | 1 | 2008 | 308 | 0.060 |
Why?
| Lipoproteins, LDL | 1 | 2005 | 131 | 0.060 |
Why?
| Blood Glucose | 3 | 2018 | 2086 | 0.060 |
Why?
| Liver Transplantation | 1 | 2013 | 800 | 0.060 |
Why?
| Biological Availability | 2 | 2012 | 129 | 0.060 |
Why?
| ErbB Receptors | 1 | 2008 | 601 | 0.060 |
Why?
| Ankle Brachial Index | 1 | 2024 | 37 | 0.060 |
Why?
| Anxiety Disorders | 2 | 2021 | 349 | 0.060 |
Why?
| Metabolome | 2 | 2018 | 316 | 0.060 |
Why?
| Tobacco Products | 2 | 2019 | 112 | 0.060 |
Why?
| Cognition Disorders | 1 | 2007 | 496 | 0.050 |
Why?
| China | 2 | 2007 | 187 | 0.050 |
Why?
| Follow-Up Studies | 3 | 2024 | 4917 | 0.050 |
Why?
| Analysis of Variance | 1 | 2006 | 1283 | 0.050 |
Why?
| Telephone | 1 | 2024 | 167 | 0.050 |
Why?
| Muscle, Skeletal | 1 | 2013 | 1629 | 0.050 |
Why?
| Time Factors | 3 | 2020 | 6568 | 0.050 |
Why?
| Sample Size | 1 | 2022 | 117 | 0.050 |
Why?
| Prognosis | 3 | 2021 | 3787 | 0.050 |
Why?
| Postoperative Complications | 1 | 2014 | 2494 | 0.050 |
Why?
| Child | 8 | 2021 | 20824 | 0.050 |
Why?
| Depressive Disorder, Major | 2 | 2020 | 347 | 0.050 |
Why?
| C-Reactive Protein | 1 | 2024 | 394 | 0.050 |
Why?
| Comorbidity | 3 | 2013 | 1542 | 0.050 |
Why?
| Pilot Projects | 2 | 2017 | 1545 | 0.050 |
Why?
| Dietary Supplements | 2 | 2015 | 533 | 0.050 |
Why?
| Nucleic Acid Amplification Techniques | 1 | 2021 | 35 | 0.050 |
Why?
| Virion | 1 | 2021 | 83 | 0.040 |
Why?
| Ontario | 1 | 2020 | 89 | 0.040 |
Why?
| Patient Selection | 2 | 2008 | 671 | 0.040 |
Why?
| Diagnostic and Statistical Manual of Mental Disorders | 2 | 2013 | 234 | 0.040 |
Why?
| Molecular Diagnostic Techniques | 1 | 2021 | 93 | 0.040 |
Why?
| Stroke | 1 | 2009 | 1111 | 0.040 |
Why?
| Serotonin | 2 | 1999 | 321 | 0.040 |
Why?
| Polymerase Chain Reaction | 2 | 2014 | 1045 | 0.040 |
Why?
| Sex Factors | 3 | 2013 | 1947 | 0.040 |
Why?
| Specimen Handling | 1 | 2021 | 163 | 0.040 |
Why?
| Opioid Peptides | 1 | 1999 | 5 | 0.040 |
Why?
| Cohort Studies | 4 | 2014 | 5394 | 0.040 |
Why?
| Computer Simulation | 3 | 2010 | 943 | 0.040 |
Why?
| Asia, Southeastern | 1 | 1998 | 11 | 0.040 |
Why?
| Escape Reaction | 1 | 1999 | 61 | 0.040 |
Why?
| Genetics, Behavioral | 1 | 2019 | 40 | 0.040 |
Why?
| Helplessness, Learned | 1 | 1999 | 62 | 0.040 |
Why?
| Potassium, Dietary | 1 | 2018 | 11 | 0.040 |
Why?
| Bayes Theorem | 1 | 2020 | 367 | 0.040 |
Why?
| Emergency Service, Hospital | 2 | 2020 | 1977 | 0.040 |
Why?
| DNA-Binding Proteins | 1 | 2005 | 1423 | 0.040 |
Why?
| United Kingdom | 1 | 2019 | 263 | 0.040 |
Why?
| Pyridinium Compounds | 1 | 2018 | 24 | 0.040 |
Why?
| Infusions, Intravenous | 2 | 1997 | 395 | 0.040 |
Why?
| Oxidative Stress | 2 | 2016 | 1220 | 0.040 |
Why?
| Methionine | 1 | 2018 | 158 | 0.040 |
Why?
| Death | 1 | 2018 | 124 | 0.040 |
Why?
| Chromosomes, Human | 1 | 2017 | 41 | 0.040 |
Why?
| Transcription Factors | 1 | 2005 | 1634 | 0.040 |
Why?
| Anxiety | 2 | 2021 | 947 | 0.040 |
Why?
| RNA, Viral | 1 | 2021 | 622 | 0.040 |
Why?
| Absorption | 1 | 1997 | 56 | 0.030 |
Why?
| Injections, Subcutaneous | 1 | 1997 | 145 | 0.030 |
Why?
| Transcriptome | 1 | 2022 | 871 | 0.030 |
Why?
| Models, Biological | 2 | 2010 | 1702 | 0.030 |
Why?
| RNA, Bacterial | 1 | 2017 | 182 | 0.030 |
Why?
| Mortality | 1 | 2018 | 310 | 0.030 |
Why?
| DNA, Bacterial | 1 | 2017 | 324 | 0.030 |
Why?
| Methemoglobin | 1 | 2015 | 20 | 0.030 |
Why?
| Fear | 1 | 1999 | 317 | 0.030 |
Why?
| Stress, Physiological | 1 | 1999 | 412 | 0.030 |
Why?
| Forearm | 1 | 2016 | 118 | 0.030 |
Why?
| Acetylcholine | 1 | 2016 | 185 | 0.030 |
Why?
| Lung Neoplasms | 1 | 2008 | 2353 | 0.030 |
Why?
| Datasets as Topic | 1 | 2016 | 108 | 0.030 |
Why?
| Fatty Acids | 1 | 2018 | 415 | 0.030 |
Why?
| Hypoglycemic Agents | 1 | 2024 | 1206 | 0.030 |
Why?
| Mental Health | 1 | 2021 | 675 | 0.030 |
Why?
| Mice, Congenic | 1 | 2015 | 22 | 0.030 |
Why?
| Lipid Metabolism | 1 | 2018 | 491 | 0.030 |
Why?
| RNA, Ribosomal, 16S | 1 | 2017 | 520 | 0.030 |
Why?
| Elasticity | 1 | 2015 | 202 | 0.030 |
Why?
| Oligonucleotide Array Sequence Analysis | 2 | 2008 | 772 | 0.030 |
Why?
| Brain Chemistry | 2 | 2009 | 115 | 0.030 |
Why?
| Glomerular Filtration Rate | 1 | 2018 | 684 | 0.030 |
Why?
| Sibling Relations | 1 | 2014 | 10 | 0.030 |
Why?
| Pulse Wave Analysis | 1 | 2015 | 252 | 0.030 |
Why?
| Urban Health | 1 | 2014 | 77 | 0.030 |
Why?
| Rural Health | 1 | 2014 | 70 | 0.030 |
Why?
| Regression Analysis | 1 | 1997 | 987 | 0.030 |
Why?
| Inheritance Patterns | 1 | 2014 | 46 | 0.030 |
Why?
| Mobility Limitation | 1 | 2014 | 62 | 0.030 |
Why?
| Mass Screening | 1 | 2021 | 1121 | 0.030 |
Why?
| Unsafe Sex | 1 | 2013 | 55 | 0.030 |
Why?
| DEAD Box Protein 58 | 1 | 2013 | 9 | 0.030 |
Why?
| Heart Failure | 1 | 2006 | 2142 | 0.030 |
Why?
| Age Distribution | 1 | 2014 | 376 | 0.030 |
Why?
| Incidence | 1 | 2019 | 2634 | 0.030 |
Why?
| Condoms | 1 | 2013 | 102 | 0.030 |
Why?
| Research Design | 1 | 1998 | 1038 | 0.020 |
Why?
| Genomics | 1 | 2017 | 715 | 0.020 |
Why?
| Microcirculation | 1 | 2012 | 141 | 0.020 |
Why?
| Apolipoproteins | 1 | 1992 | 38 | 0.020 |
Why?
| Vasodilation | 1 | 2015 | 480 | 0.020 |
Why?
| Mice | 3 | 2015 | 16543 | 0.020 |
Why?
| Drug Tolerance | 1 | 1992 | 82 | 0.020 |
Why?
| Hospitalization | 1 | 2021 | 2080 | 0.020 |
Why?
| Interferons | 1 | 2013 | 187 | 0.020 |
Why?
| Logistic Models | 1 | 2016 | 1963 | 0.020 |
Why?
| Vascular Resistance | 1 | 2012 | 373 | 0.020 |
Why?
| Urban Population | 1 | 2014 | 436 | 0.020 |
Why?
| Infusions, Parenteral | 1 | 1991 | 39 | 0.020 |
Why?
| Muscle Strength | 1 | 2014 | 305 | 0.020 |
Why?
| Phobic Disorders | 1 | 2011 | 29 | 0.020 |
Why?
| Neurons | 1 | 1999 | 1425 | 0.020 |
Why?
| Attention Deficit and Disruptive Behavior Disorders | 1 | 2011 | 60 | 0.020 |
Why?
| Nitric Oxide | 1 | 2015 | 892 | 0.020 |
Why?
| Cross-Over Studies | 1 | 2012 | 513 | 0.020 |
Why?
| Animals | 5 | 2015 | 34628 | 0.020 |
Why?
| Rodentia | 1 | 2010 | 47 | 0.020 |
Why?
| Sodium Chloride | 1 | 1991 | 141 | 0.020 |
Why?
| Recovery of Function | 1 | 2014 | 641 | 0.020 |
Why?
| Fluid Therapy | 1 | 1991 | 135 | 0.020 |
Why?
| Recurrence | 1 | 2013 | 1013 | 0.020 |
Why?
| Nuclear Family | 1 | 2009 | 50 | 0.020 |
Why?
| Dizziness | 1 | 2010 | 80 | 0.020 |
Why?
| Mice, Inbred Strains | 1 | 2010 | 407 | 0.020 |
Why?
| Coronary Disease | 1 | 1992 | 389 | 0.020 |
Why?
| Alcohol-Induced Disorders, Nervous System | 1 | 2009 | 6 | 0.020 |
Why?
| Vitamin B 6 | 1 | 2009 | 9 | 0.020 |
Why?
| Inflammation | 1 | 2020 | 2694 | 0.020 |
Why?
| Principal Component Analysis | 1 | 2010 | 185 | 0.020 |
Why?
| Biopsy | 1 | 2013 | 1093 | 0.020 |
Why?
| Fertility | 1 | 2010 | 161 | 0.020 |
Why?
| Vitamin B Complex | 1 | 2009 | 41 | 0.020 |
Why?
| Chi-Square Distribution | 1 | 2009 | 513 | 0.020 |
Why?
| Tetraspanins | 1 | 2008 | 15 | 0.020 |
Why?
| Vitamin B 12 | 1 | 2009 | 120 | 0.020 |
Why?
| Dose-Response Relationship, Drug | 1 | 2012 | 1968 | 0.020 |
Why?
| Receptors, Opioid, mu | 1 | 2008 | 57 | 0.020 |
Why?
| Medical History Taking | 1 | 2008 | 119 | 0.020 |
Why?
| Folic Acid | 1 | 2009 | 182 | 0.020 |
Why?
| Internet | 1 | 2012 | 616 | 0.020 |
Why?
| Sri Lanka | 1 | 2007 | 7 | 0.020 |
Why?
| Bias | 1 | 2008 | 196 | 0.020 |
Why?
| Preoperative Care | 1 | 2009 | 343 | 0.020 |
Why?
| Energy Intake | 1 | 2010 | 453 | 0.020 |
Why?
| Bangladesh | 1 | 2007 | 42 | 0.020 |
Why?
| Pakistan | 1 | 2007 | 75 | 0.020 |
Why?
| Disability Evaluation | 1 | 2009 | 290 | 0.020 |
Why?
| India | 1 | 2007 | 167 | 0.020 |
Why?
| Kaplan-Meier Estimate | 1 | 2009 | 861 | 0.020 |
Why?
| Age of Onset | 1 | 2007 | 494 | 0.020 |
Why?
| Genes, Recessive | 1 | 2006 | 75 | 0.020 |
Why?
| Glucose Tolerance Test | 1 | 2007 | 356 | 0.020 |
Why?
| Data Collection | 1 | 2008 | 652 | 0.020 |
Why?
| Promoter Regions, Genetic | 1 | 2010 | 1194 | 0.020 |
Why?
| Linear Models | 1 | 2007 | 817 | 0.020 |
Why?
| Dyslipidemias | 1 | 2007 | 176 | 0.020 |
Why?
| 3' Untranslated Regions | 1 | 2005 | 137 | 0.010 |
Why?
| Heterozygote | 1 | 2005 | 268 | 0.010 |
Why?
| Proportional Hazards Models | 1 | 2007 | 1221 | 0.010 |
Why?
| Liver | 1 | 2013 | 1832 | 0.010 |
Why?
| Smoking Cessation | 1 | 2008 | 409 | 0.010 |
Why?
| Asthma | 2 | 2010 | 2258 | 0.010 |
Why?
| Randomized Controlled Trials as Topic | 1 | 2010 | 1366 | 0.010 |
Why?
| Disease Models, Animal | 1 | 2014 | 3994 | 0.010 |
Why?
| Mice, Inbred C57BL | 1 | 2014 | 5270 | 0.010 |
Why?
| Rats, Sprague-Dawley | 2 | 1999 | 2308 | 0.010 |
Why?
| RNA | 1 | 2010 | 877 | 0.010 |
Why?
| Interleukin-10 | 1 | 2005 | 299 | 0.010 |
Why?
| Intracellular Signaling Peptides and Proteins | 1 | 2006 | 420 | 0.010 |
Why?
| Retrospective Studies | 1 | 2020 | 14546 | 0.010 |
Why?
| Overweight | 1 | 2007 | 522 | 0.010 |
Why?
| Glucose | 1 | 2007 | 976 | 0.010 |
Why?
| Parents | 1 | 2010 | 1301 | 0.010 |
Why?
| DNA | 1 | 2008 | 1406 | 0.010 |
Why?
| Rats | 2 | 1999 | 5236 | 0.010 |
Why?
| Membrane Proteins | 1 | 2006 | 1100 | 0.010 |
Why?
| Microinjections | 1 | 1999 | 78 | 0.010 |
Why?
| Reinforcement Schedule | 1 | 1999 | 30 | 0.010 |
Why?
| Periaqueductal Gray | 1 | 1999 | 16 | 0.010 |
Why?
| Electroshock | 1 | 1999 | 143 | 0.010 |
Why?
| Insulin Resistance | 1 | 2007 | 1163 | 0.010 |
Why?
| Proto-Oncogene Proteins c-fos | 1 | 1999 | 173 | 0.010 |
Why?
| Naltrexone | 1 | 1999 | 86 | 0.010 |
Why?
| Catheterization | 1 | 1999 | 176 | 0.010 |
Why?
| Morphine | 1 | 1999 | 128 | 0.010 |
Why?
| Narcotic Antagonists | 1 | 1999 | 162 | 0.010 |
Why?
| Insulin | 1 | 2007 | 2311 | 0.010 |
Why?
| Infant | 1 | 2008 | 8994 | 0.010 |
Why?
| Child, Preschool | 1 | 2008 | 10457 | 0.010 |
Why?
| Hyaluronoglucosaminidase | 1 | 1991 | 9 | 0.010 |
Why?
| Tritium | 1 | 1991 | 74 | 0.010 |
Why?
| Analgesics, Opioid | 1 | 1999 | 914 | 0.010 |
Why?
| Evaluation Studies as Topic | 1 | 1991 | 175 | 0.010 |
Why?
| Depression | 1 | 1999 | 1289 | 0.010 |
Why?
|
|
McQueen's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|